HAIKOU CITY, China, Feb. 11 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, announced today that the company has initiated clinical trials for the generic version of the leading hypertension drug Candesartan.
The clinical trials for this product are anticipated to require approximately 18 months to complete. The sartan group of drugs, used as front- line therapy in the treatment of hypertension, are usually well-tolerated, and have a high safety record. Candesartan was discovered and originally synthesized by the Japanese firm, Takeda Pharmaceutical Company Limited and jointly developed by the same company with AstraZeneca. Worldwide sales for 2007 exceeded $2.5 billion(1). In China, Candesartan is listed on the National Basic Medical Insurance Drug List, enabling patient reimbursement.
China Pharma's CEO and president, Ms Zhilin Li, commented, ''In China
today, nearly 60% of all urban adults aged 65 years and over suffer from
hypertension(2). Moreover, due to the aging of the population and changes in
lifestyle, the urban prevalence of hypertension has been predicted to grow to
100 million by 2011(2). Even in 2004, sales in China of anti-hypertension
drugs exceeded CNY 10 billion ($1.2 billion, Dec. 2004), exhibiting a market
growth of over 30% year on year, and accounting for 22% of all cardiovascular
system drugs sold in China(3). Hypertension is a serious problem and is linked
to an increased incidence of other diseases, particularly brain edema,
coronary heart disease and diabetes. Candesartan is a well established
hypertension drug and is known to be particularly suitable for heart failure
and diabetic patients. Our R&D strategy is to enable us to provide more
effective treatment for the high numbers of patients in China whose medication
needs are serious
|SOURCE China Pharma Holdings, Inc.|
Copyright©2009 PR Newswire.
All rights reserved